Global Neurodegenerative Diseases Drugs Market Report and Forecast 2023-2028

Global Neurodegenerative Diseases Drugs Market Report and Forecast 2023-2028


Market Outlook

According to the report by Expert Market Research (EMR), the global neurodegenerative diseases drugs market reached a value of USD 41.73 billion in 2022. Aided by the expanding geriatric population and the mounting prevalence of neurodegenerative disorders, the market is projected to further grow at a CAGR of 7.10% between 2023 and 2028.

Neurodegenerative diseases are conditions characterised by the progressive degeneration or death of nerve cells, also known as neurons. Notable illnesses under this category include Alzheimer's disease, Parkinson's disease, and Huntington's disease, among others. Drugs designed to treat these ailments primarily aim to alleviate symptoms, decelerate disease progression, and improve the patient's quality of life. With the complexity of the human brain and the diseases that afflict it, research in this realm has been both intricate and intensive.

As per the global neurodegenerative diseases drugs market analysis, the market is predominantly influenced by the upsurge in the elderly population worldwide. Ageing remains a principal risk factor for many neurodegenerative disorders. As the global population experiences increased longevity, the occurrence of these diseases has inevitably risen, leading to heightened demand for effective therapeutic interventions.

Simultaneously, the intensifying awareness about neurodegenerative diseases and their early symptoms has played a pivotal role in boosting the demand for related drugs. Public health initiatives and campaigns have illuminated the signs and consequences of these conditions, fostering early detection and subsequent treatment. This proactive approach to neurodegenerative diseases translates to increased demand for therapeutic drugs.

Moreover, innovative breakthroughs and persistent research and development activities in the pharmaceutical sector substantially propel the neurodegenerative diseases drugs market demand. New drug discoveries, combined with advanced therapeutic techniques, promise better management of these diseases, furthering the appeal of the market for neurodegenerative diseases drugs. Collaborations between pharma giants and biotech startups have also hastened drug discovery processes, leading to more robust pipelines and quicker drug approvals.

Beyond these factors, the neurodegenerative diseases drugs market growth is invigorated by technological advancements in diagnostic methodologies. Enhanced imaging technologies, genetic testing, and biomarker analysis facilitate the early and accurate diagnosis of neurodegenerative diseases. An early diagnosis often necessitates timely drug interventions, thereby indirectly bolstering the demand for neurodegenerative diseases drugs.

Market Segmentation

The market can be divided based on drug class, disease indication, route of administration, end-user, and region.

Market Breakup by Drug Class
  • Immunomodulator
  • Interferons
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Others
Market Breakup by Disease Indication
  • Multiple Sclerosis
  • Parkinson’s Disease
  • Alzheimer's Disease
  • Spinal Muscular Atrophy (SMA)
  • Others
Market Breakup by Route of Administration
  • Oral
  • Injection
  • Transdermal
Market Breakup by End-User
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online
Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Competitive Landscape

The EMR report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the global neurodegenerative diseases drugs market. Some of the major players explored in the report by Expert Market Research are as follows:
  • Pfizer, Inc.
  • Merck KGaA
  • Novartis AG
  • Acadia Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd
  • Others
About Us

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analyses provide the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today's competitive market.

Don't miss the opportunity to elevate your business intelligence and fortify your strategic planning. Secure your organisation's future success by acquiring one of our Expert Market Research reports today.

*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.


1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Region
7 Industry Opportunities and Challenges
8 Global Neurodegenerative Diseases Drugs Market Analysis
8.1 Key Industry Highlights
8.2 Global Neurodegenerative Diseases Drugs Historical Market (2018-2022)
8.3 Global Neurodegenerative Diseases Drugs Market Forecast (2023-2028)
8.4 Global Neurodegenerative Diseases Drugs Market by Drug Class
8.4.1 Immunomodulator
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Interferons
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 Decarboxylase Inhibitors
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.4.4 Dopamine Agonists
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2018-2022)
8.4.4.3 Forecast Trend (2023-2028)
8.4.5 Others
8.5 Global Neurodegenerative Diseases Drugs Market by Disease Indication
8.5.1 Multiple Sclerosis
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Parkinson’s Disease
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Alzheimer's Disease
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2022)
8.5.3.3 Forecast Trend (2023-2028)
8.5.4 Spinal Muscular Atrophy (SMA)
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2022)
8.5.4.3 Forecast Trend (2023-2028)
8.5.5 Others
8.6 Global Neurodegenerative Diseases Drugs Market by Route of Administration
8.6.1 Oral
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 Injection
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.3 Transdermal
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2022)
8.6.3.3 Forecast Trend (2023-2028)
8.7 Global Neurodegenerative Diseases Drugs Market by End-User
8.7.1 Hospital Pharmacy
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2022)
8.7.1.3 Forecast Trend (2023-2028)
8.7.2 Retail Pharmacy
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2022)
8.7.2.3 Forecast Trend (2023-2028)
8.7.3 Online
8.7.3.1 Market Share
8.7.3.2 Historical Trend (2018-2022)
8.7.3.3 Forecast Trend (2023-2028)
8.8 Global Neurodegenerative Diseases Drugs Market by Region
8.8.1 Market Share
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2022)
9.3.2 Forecast Trend (2023-2028)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2022)
9.4.2 Forecast Trend (2023-2028)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2022)
9.5.2 Forecast Trend (2023-2028)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Pfizer, Inc.
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Merck KGaA
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Novartis AG
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Acadia Pharmaceuticals Inc.
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Teva Pharmaceutical Industries Ltd.
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 F. Hoffmann-La Roche Ltd
11.2.6.1 Company Overview
11.2.6.2 Product Portfolio
11.2.6.3 Demographic Reach and Achievements
11.2.6.4 Certifications
11.2.7 Others
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Neurodegenerative Diseases Drugs Market: Key Industry Highlights, 2018 and 2028
2. Global Neurodegenerative Diseases Drugs Historical Market: Breakup by Drug Class (USD Million), 2018-2022
3. Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by Drug Class (USD Million), 2023-2028
4. Global Neurodegenerative Diseases Drugs Historical Market: Breakup by Disease Indication (USD Million), 2018-2022
5. Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by Disease Indication (USD Million), 2023-2028
6. Global Neurodegenerative Diseases Drugs Historical Market: Breakup by Route of Administration (USD Million), 2018-2022
7. Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by Route of Administration (USD Million), 2023-2028
8. Global Neurodegenerative Diseases Drugs Historical Market: Breakup by End-User (USD Million), 2018-2022
9. Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by End-User (USD Million), 2023-2028
10. Global Neurodegenerative Diseases Drugs Historical Market: Breakup by Region (USD Million), 2018-2022
11. Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by Region (USD Million), 2023-2028
12. North America Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
13. North America Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Europe Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
15. Europe Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Asia Pacific Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
17. Asia Pacific Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Latin America Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
19. Latin America Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
20. Middle East and Africa Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
21. Middle East and Africa Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
22. Global Neurodegenerative Diseases Drugs Market Structure.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings